# Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients

> **NCT02416778** · PHASE4 · UNKNOWN · sponsor: **Georg-Christian Funk** · enrollment: 20 (estimated)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion

## Key facts

- **NCT ID:** NCT02416778
- **Lead sponsor:** Georg-Christian Funk
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-02
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2016-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02416778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02416778, "Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02416778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*